Latest News

FDA designates OPN-2853 as an orphan drug for myelofibrosis, showing promising results in spleen size reduction and safety in clinical trials.

New cancer vaccine MVP-S shows promising results in recurrent ovarian cancer, enhancing immune response and improving treatment outcomes with pembrolizumab.

Combination therapies using PD-1/PD-L1 inhibitors enhance survival rates in relapsed/refractory acute lymphoblastic leukemia without added toxicity.

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.

A groundbreaking trial reveals the promising efficacy of fruquintinib and sintilimab for advanced endometrial cancer, offering new hope for patients.

The FDA released draft guidance on minimal residual disease and complete response as trial end points to accelerate multiple myeloma drug approvals.

A new study reveals that combining ianalumab with ibrutinib offers promising results for chronic lymphocytic leukemia, enabling some patients to stop therapy.

Nivolumab after CAR T-cell therapy failure produced responses in only a small percentage of patients with myeloma or non-Hodgkin lymphoma, although responses in myeloma appeared durable.

FDA fast-tracks BNT113, an mRNA immunotherapy, for treating HPV16+ head and neck cancer, enhancing immune responses alongside pembrolizumab.

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas for multiple myeloma and what will come next now that this data set has been made available.

The FDA granted Orphan Drug Designation to LP-284, a small molecule targeting DNA damage repair mechanisms, for soft tissue sarcoma.

Sofetabart mipitecan receives FDA breakthrough therapy designation, showing promising efficacy in treating platinum-resistant ovarian cancer.

Zenocutuzumab shows promising efficacy in advanced NRG1+ pancreatic and cholangiocarcinoma, offering hope for patients after disease progression.

An mRNA neoantigen therapy maintained long-term recurrence-free survival as an adjuvant for melanoma, compared with pembrolizumab alone.

The FDA reviews gedatolisib, a promising treatment for advanced breast cancer, aiming to enhance patient outcomes with innovative combination therapies.

Early findings from the QUILT-106 trial reveal promising outcomes for CD19 CAR-NK cell therapy combined with rituximab in treating Waldenstrom lymphoma.

The FDA reviews ropeginterferon alfa-2b-njft for essential thrombocythemia, showing promising efficacy in clinical trials for patients.

New trial data reveals promising results for pelareorep and atezolizumab in treating advanced anal cancer, significantly improving response rates and duration.

AI revolutionizes cancer care by enhancing detection, diagnosis, and personalized treatment, promising improved outcomes and efficiency in oncology.

Epcoritamab shows promising results in improving progression-free survival for patients with relapsed/refractory DLBCL, paving the way for future therapies.

EMA validates T-DXd and pertuzumab for first-line HER2-positive metastatic breast cancer, potentially transforming treatment standards in the EU.

New research highlights amivantamab's potential in enhancing treatment outcomes for RAS/BRAF wild-type metastatic colorectal cancer, addressing resistance to standard therapies.

Discover the latest breakthroughs in oncology, including advancements in lung cancer treatments and FDA updates on promising therapies.

A new study reveals that savolitinib and osimertinib significantly enhance survival in advanced EGFR-mutated lung cancer, outperforming traditional chemotherapy.

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating lymphocytes in patients with melanoma.

Nivolumab plus AVD shows significant improvement in progression-free survival for advanced Hodgkin lymphoma, establishing it as a preferred treatment option.

Investigational therapy [212Pb]VMT-α-NET shows promising antitumor activity in advanced neuroendocrine tumors, with ongoing trials and favorable safety profile.

The FDA designates ICT01 as a breakthrough therapy for unfit AML patients, showcasing promising efficacy in early clinical trials.